timothy sykes logo
Altimmune’s Stock Target Raised as MASH Program Gains Momentum Thumbnail
G Google News

Altimmune’s Stock Target Raised as MASH Program Gains Momentum

TIM SYKES•UPDATED APR. 4, 2026, 11:05 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Altimmune Inc.’s stocks have been trading up by 7.05 percent after promising clinical trial results sparked investor enthusiasm.

Candlestick Chart

Weekly Update Mar 30 – Apr 03, 2026: On Saturday, April 04, 2026 Altimmune Inc. stock [NASDAQ: ALT] is trending up by 7.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Altimmune (ALT) is situated precariously within the healthcare sector, as highlighted by its extreme profitability metrics such as a pretax profit margin of -9405.8 and a gross margin of 100%. Its financials reveal a challenging landscape: a revenue figure of just $41,000 against an enterprise value of $364.47 million, indicating significant overvaluation at a price-to-sales ratio of 10598.81. Moreover, the company’s management effectiveness ratios such as return on equity of -48.91 and return on assets of -42.95 further underscore its operational inefficiencies. Collectively, these indicators highlight Altimmune’s struggle to convert its high cash reserves and investments into sustainable profitability.

Recent price trends in Altimmune’s stock show a cautiously optimistic phase with stocks climbing steadily. The notable price increase from $2.88 to $3.34 over the recorded period indicates budding bullish momentum. This upward trend is well-supported by consistent bullish candlestick formations and significant price volume consolidation at these levels, suggesting potential investor optimism. For traders, a strategic entry point might be considered at a pullback near the $3.12 level, with expectations for resistance at $3.34. Keeping a close watch on these critical levels while volumes remain supportive of an upside move could offer short-term trading opportunities.

The prognosis for Altimmune hinges significantly on its development pipeline, which is receiving notable attention. Analysts have adjusted their price targets reflecting changes in sentiment; H.C. Wainwright’s upward revision to $25 is buoyed by Altimmune’s bold focus on pemvidutide for MASH and alcohol-related liver diseases. Despite setbacks, including a significant Q4 loss, the broader healthcare indices highlight a more resilient trajectory, with analyst recommendations sustaining a ‘Buy’ rating. Expectations of impactful Phase 3 trials and Phase 2 data releases by late 2026 could act as key catalysts. Notable resistance levels for ALT exist at $3.50, with a foundational support level at $3.12. Given its potential and industry dynamics, the sentiment on Altimmune leans towards a cautiously optimistic outlook.

Quick Financial Overview

Recent months have painted a dynamic picture for Altimmune’s financial trajectory. Despite reporting a wider-than-expected loss in the fourth quarter with an EPS of -$0.27, the company remains optimistic due to the promising prospects of its lead drug, pemvidutide. Garnering immense attention, this compound is poised for a critical Phase 3 trial as part of Altimmune’s ambitious metabolic and liver disease strategy.

Financial metrics reveal Altimmune’s continued focus on strategic investments, as evidenced by cash flows dedicated to operational and trial expansions. While the headline loss may seem daunting, delving deeper into their financial health shows a robust cash reserve of $34.5 million, indispensable for advancing clinical trials and executing their strategic vision.

Current stock performance showcases resilience, bolstered by revamped insights and algorithmic trading volumes, as reflected by a recent close at $3.34. Statistically, Altimmune’s financial groundwork indicates preparedness for high-stakes execution in the upcoming quarters. Its staggering price-to-sales ratio, though high, correlates with its advanced phase pipeline drugs, projecting a promising horizon amid wall street confidence.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading ALT

Millionaire's
POV on ALT

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”